Evidence map›Paper›PMID 30022576›Full record

ArticleAddiction biology2019

Mammalian target of rapamycin complex 1 and its downstream effector collapsin response mediator protein-2 drive reinstatement of alcohol reward seeking.

Sami Ben Hamida, Sophie Laguesse, Nadege Morisot, Jong-Hyun Park, Khanhky Phuamluong, Anthony L Berger, Ki Duk Park, Dorit Ron

Abstract read
In one paragraph

Article in Addiction biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Alcohol and the brain: from genes to circuits.Trends in neurosciences · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Protein Translation and Psychiatric Disorders.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2020
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sami Ben HamidaDepartment of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0001-9636-9432
Sophie LaguesseDepartment of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0002-9217-0087
Nadege MorisotDepartment of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0003-1674-9406
Jong-Hyun ParkConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of Science and Technology (KIST), Republic of Korea.ORCID 0000-0002-9463-6055
Khanhky PhuamluongDepartment of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0002-0168-2459
Anthony L BergerDepartment of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0002-6921-7713
Ki Duk ParkConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of Science and Technology (KIST), Republic of Korea.ORCID 0000-0002-7753-214X
Dorit RonDepartment of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0001-5161-967X

Funding

Vector, Transgenic, and Imaging CoreP50AA017072 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RON, DORIT · 2008 to 2017
$13.9M
mTOR Signaling and Alcohol Use DisorderR01AA027474 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RON, DORIT · 2018 to 2022
$1.6M
NIAAA NIH HHS P50 AA017072NIAAA NIH HHS R01 AA027474
6 · The paper itself

Abstract

Alcohol use disorder is a chronic relapsing disease. Maintaining abstinence represents a major challenge for alcohol-dependent patients. Yet the molecular underpinnings of alcohol relapse remain poorly understood. In the present study, we investigated the potential role of the mammalian target of rapamycin complex 1 (mTORC1) in relapse to alcohol-seeking behavior by using the reinstatement of a previously extinguished alcohol conditioned place preference (CPP) response as a surrogate relapse paradigm. We found that mTORC1 is activated in the nucleus accumbens shell following alcohol priming-induced reinstatement of alcohol place preference. We further report that the selective mTORC1 inhibitor, rapamycin, abolishes reinstatement of alcohol place preference. Activation of mTORC1 initiates the translation of synaptic proteins, and we observed that reinstatement of alcohol CPP is associated with increased protein levels of one of mTORC1's downstream targets, collapsin response mediator protein-2 (CRMP2), in the nucleus accumbens. Importantly, the level of mTORC1 activation and CRMP2 expression positively correlate with the CPP score during reinstatement. Finally, we found that systemic administration of the CRMP2 inhibitor, lacosamide, attenuates alcohol priming-induced reinstatement of CPP. Together, our results reveal that mTORC1 and its downstream target, CRMP2, contribute to mechanisms underlying reinstatement of alcohol reward seeking. Our results could have important implications for the treatment of relapse to alcohol use and position the Food and Drug Administration approved drugs, rapamycin and lacosamide, for the treatment of alcohol use disorder.

Indexed as

AnimalsCentral Nervous System AgentsCentral Nervous System DepressantsConditioning, OperantDrug-Seeking BehaviorEthanolExtinction, PsychologicalIntercellular Signaling Peptides and ProteinsLacosamideMaleMechanistic Target of Rapamycin Complex 1Mice, Inbred DBANerve Tissue ProteinsReinforcement, PsychologyRewardSelf AdministrationCentral Nervous System AgentsCentral Nervous System Depressantscollapsin response mediator protein-2EthanolIntercellular Signaling Peptides and ProteinsLacosamideMechanistic Target of Rapamycin Complex 1Nerve Tissue ProteinsalcoholCRMP2mTOR

Identifiers

PMID30022576
PMCPMC7255088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.